Droperidol Intravenous for Adults

Who can administer

Administration RESTRICTED - see Appendix 1

Important information

- Contraindicated in patients with known or suspected prolonged **QT interval**
- Avoid use with **medications which also cause QTc prolongation**
- Cardiovascular monitoring required (see monitoring requirements below)

Available preparations

Droperidol (Panpharma) 2.5mg per 1mL ampoule (unlicensed)

Reconstitution

Already in solution

Draw up using a 5 micron filter needle

Methods of intravenous administration

Slow intravenous injection

- Administer over at least 3 minutes [ref 1]

Dose in adults

Prevention and treatment of post-operative nausea and vomiting (PONV)

- Adults: 0.625 to 1.25mg (see also further information)
- Elderly: maximum 0.625mg
- May be repeated every six hours as required
- **Renal/hepatic impairment: maximum 0.625mg (caution advised** in renal and hepatic impairment)
- **Administration** of droperidol is **recommended 30 minutes before the anticipated end of surgery**

Monitoring

- Continuous pulse oximetry should be performed in patients with known or suspected risk of ventricular arrhythmia and should continue for 30 minutes following single intravenous administration [ref 1]
- ECG monitoring if cardiovascular risk factors[ref 1]
- Monitor blood pressure and heart rate[ref 1]

Further information

- The manufacturers suggest that droperidol may be added to PCA. However, this is not practice within GUH. See SPC for further details

Storage

Store below 25^{0}C

References

Droperidol (Aguettant) downloaded March 2025

1: Medusa http://medusa.wales.nhs.uk/ accessed online 23rd Feb 2023

Therapeutic classification

Anti-emetic, Butyrophenone neuroleptic

BNF
CNS